Sesen Bio to pay $0.36/share special dividend and issue CVR upon merger close on March 7

Carisma Therapeutics Inc.

Special cash dividend of $75M (~$0.36/share) payable by March 10 to holders of record March 7, contingent on merger closing.
Each share receives one Contingent Value Right for potential proceeds from sale of Vicineum/preclinical assets and Roche milestone.
Merger with CARISMA Therapeutics approved by stockholders on March 2, expected to close March 7.
Dividend and CVR issuance contingent on closing of merger with CARISMA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.